-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651.O3.6 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Revealing Subclonal Heterogeneity in Multiple Myeloma

Myeloma: Biology and Pathophysiology, excluding Therapy Program: Oral and Poster Abstracts
Type: Oral
Saturday, December 5, 2015: 7:30 AM-9:00 AM
Tangerine 1 (WF1), Level 2 (Orange County Convention Center)
Moderators:
Patricia Maiso, PhD, Dana-Farber Cancer Institute and Robert Z. Orlowski, Ph.D., M.D., The University of Texas MD Anderson Cancer Center

Disclosures:
No relevant conflicts of interest to declare.
7:30 AM

Bruno Paiva, PhD1*, Noemi Puig, MD, PhD2*, Paula Arana3*, Teresa Cedena4*, Lourdes Cordon5*, Maria Belen Vidriales, MD, PhD2*, Norma C Gutierrez6*, Joaquin Martinez-López, MD.PhD7*, Miguel T Hernandez8*, Ana Isabel Teruel, MD9*, Mercedes Gironella10*, M Asuncion Echeveste11*, Laura Rosiñol, MD PhD12*, Rafael Martinez, MD13*, Albert Oriol, MD PhD14*, Javier De La Rubia15*, Joan Blade, MD PhD12, Juan Jose Lahuerta16*, Maria-Victoria Mateos17 and Jesus San Miguel, MD PhD18*

1Department of Hematology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain
2Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
3Clinica Universidad de Navarra, Pamplona, Spain
4Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
5Hospital Universitario La Fe, Valencia, Spain
6Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Salamanca, Spain
7Hematology, Hospital 12 de Octubre, Madrid, Spain
8Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
9Hospital Clinico de Valencia, Valencia, Spain
10Hospital Universitari Vall dHebron, Barcelona, Spain
11Hospital Universitario Donostia, San Sebastian, Spain
12Hospital Clinic de Barcelona, Barcelona, Spain
13Hospital Clinico, Madrid, Spain
14Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain
15H.U.P. La Fe, Valencia, Spain
16Hospital 12 de Octubre, Madrid, Spain
17Hematology Department, University Hospital of Salamanca/IBSAL, Salamanca, Spain
18Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain

7:45 AM

Niels Weinhold, PhD1*, Shweta S. Chavan, PhD1*, Christoph Heuck, MD1, Owen W Stephens, PhD1*, Ruslana Tytarenko1*, Michael Bauer1*, Erich Allen Peterson, PhD, BS, MS1*, Timothy C. Ashby1*, Tobias Meissner2*, Caleb K. Stein, MS1*, Donald Johann, MD, MS1, Sarah K. Johnson, PhD1, Shmuel Yaccoby, PhD1, Joshua Epstein, DSc1, Frits van Rhee, MD, PhD1, Maurizio Zangari, MD1, Carolina Schinke, MD1*, Sharmilan Thanendrarajan, MD1, Faith E Davies, MD1, Bart Barlogie, MD, PhD1 and Gareth J Morgan, MD PhD1

1Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
2Department of Molecular and Experimental Medicine, Avera Cancer Institute, La Jolla, CA

8:00 AM

Nikhil C. Munshi, MD1,2, Stephane Minvielle3*, Yu-Tzu Tai, PhD1, Mariateresa Fulciniti4, Mehmet K Samur, Ph.D4*, Paul G. Richardson, MD4, Michel Attal5, Philippe Moreau3*, Florence Magrangeas3*, Kenneth C Anderson4, Malek Faham, MD, PhD6 and Herve Avet-Loiseau5*

1Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA
2Boston Veterans Administration Healthcare System, West Roxbury, MA
3Centre de Recherche en Cancérologie Nantes-Angers UMR Inserm 892—CNRS 6299 and Institut de Recherche Thérapeutique de l’Université de Nantes (IRT-UN), Nantes, France
4The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
5Unité de Génomique du Myélome, CHU Rangueil, Toulouse, France
6Adaptive Biotechnologies Corp., South San Francisco, CA

8:15 AM

Rakesh Verma, PhD1, Till Strowig, PhD2*, Rituparna Das, PhD1*, Srinivas Koduru, PhD1*, Anja Hafemann, PhD3*, Stephanie Hopf3*, Mehmet H. Kocoglu, MD4, Chiara Borsotti, PhD5*, Lin Zhang1*, Andrew R Branagan, MD1, Elizabeth Eynon, PhD3*, Markus Manz, MD6, Richard Flavell, Ph.D3* and Madhav V Dhodapkar, MD1

1Yale Cancer Center, New Haven, CT
2Microbial Immune Regulation junior research group, Helmholtz Centre for Infection Research, Braunschweig, Germany
3Department of Immunobiology, Yale School of Medicine, New Haven, CT
4Department of Medicine and Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
5Department of Hematology, University Hospital Zurich, Zurich, Switzerland
6Division of Hematology, University Hospital Zurich, Zurich, Switzerland

8:30 AM

Yuji Mishima, PhD1*, Bruno Paiva, PhD2*, Jiantao Shi3*, Mira Massoud4*, Salomon Manier, MD1, Ludmila Flores4*, Adriana Perilla-Glen, MBA1*, Yosra Aljawai, MSc1*, Daisy Huynh, BS, MS1*, Satoshi Takagi, PhD1, Aldo M Roccaro, MD, PhD1, Antonio Sacco, BS1*, Diego Alignani2*, Maria Victoria Mateos5*, Joan Bladé, MD6, Juan Jose Lahuerta7*, Paul G. Richardson, MD1, Jacob P. Laubach, MD8, Robert L. Schlossman, MD8, Kenneth C Anderson, MD1, Nikhil C. Munshi, MD1, Felipe Prosper, MD9, Franziska Michor, PhD3*, J.F. San Miguel9 and Irene M. Ghobrial, MD10

1Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Clínica Universidad de Navarra, Pamplona, Spain
3Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
4Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
5Hematolgy, Hospital Universitario de Salamanca, Salamanca, Spain
6Amyloidosis and Myeloma Unit, Department of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
7Hospital 12 de Octubre, Madrid, Spain
8Dana-Farber Cancer Institute, Boston, MA
9Clinica Universidad de Navarra, Pamplona, Spain
10Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

8:45 AM

Carolina Terragna, PhD1*, Marina Martello, PhD1*, Mauro Procacci1*, Flavio Mignone2*, Annalisa Pezzi, PhD1*, Barbara Santacroce1*, Lucia Pantani, MD1*, Igor Saggese2*, Torsten Haferlach3, Elena Zamagni1*, Enrica Borsi, PhD1*, Paola Tacchetti, MD1*, Beatrice A Zannetti, MD1*, Serena Rocchi, MD1*, Katia Mancuso, MD1*, Flores A Dico1*, Giovanni Martinelli, MD, PhD1 and Michele Cavo1*

1DIMES - Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology, University of Bologna, Bologna, Italy
2Dipartimento Scienze e Innovazione Tecnologica, Università Piemonte Orientale, Alessandria, Italy
3MLL Munich Leukemia Laboratory, Munich, Germany

*signifies non-member of ASH